These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
354 related items for PubMed ID: 32568642
21. CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease. Hoh BL, Gong Y, McDonough CW, Waters MF, Royster AJ, Sheehan TO, Burkley B, Langaee TY, Mocco J, Zuckerman SL, Mummareddy N, Stephens ML, Ingram C, Shaffer CM, Denny JC, Brilliant MH, Kitchner TE, Linneman JG, Roden DM, Johnson JA. J Neurosurg; 2016 Jun; 124(6):1746-51. PubMed ID: 26587656 [Abstract] [Full Text] [Related]
22. Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles. Lin J, Han Z, Wang C, Yi X, Chai Z, Zhou Q, Huang R. Eur J Clin Pharmacol; 2018 Sep; 74(9):1131-1140. PubMed ID: 29804161 [Abstract] [Full Text] [Related]
23. Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA. Wang Y, Meng X, Wang A, Xie X, Pan Y, Johnston SC, Li H, Bath PM, Dong Q, Xu A, Jing J, Lin J, Niu S, Wang Y, Zhao X, Li Z, Jiang Y, Li W, Liu L, Xu J, Chang L, Wang L, Zhuang X, Zhao J, Feng Y, Man H, Li G, Wang B, CHANCE-2 Investigators. N Engl J Med; 2021 Dec 30; 385(27):2520-2530. PubMed ID: 34708996 [Abstract] [Full Text] [Related]
24. Clinical and cost-effectiveness of clopidogrel resistance genotype testing after ischaemic stroke or transient ischaemic attack: a systematic review and economic model. Carroll J, Lopez Manzano C, Tomlinson E, Sadek A, Cooper C, Jones HE, Rowsell L, Knight J, Mumford A, Palmer R, Hollingworth W, Welton NJ, Whiting P. Health Technol Assess; 2024 Sep 30; 28(57):1-194. PubMed ID: 39269241 [Abstract] [Full Text] [Related]
25. Impact of CYP2C19 Polymorphisms on Clinical Outcomes and Antiplatelet Potency of Clopidogrel in Caucasian Poststroke Survivors. Tomek A, Matʼoška V, Frýdmanová A, Magerová H, Šrámek M, Paulasova-Schwabová J, Růžičková T, Janský P, Šarbochová I, Hadačová I, Kaplan V, Lacinová Z, Táborský L, Serebruany V. Am J Ther; 2018 Sep 30; 25(2):e202-e212. PubMed ID: 29509167 [Abstract] [Full Text] [Related]
26. Outcomes Associated With Clopidogrel-Aspirin Use in Minor Stroke or Transient Ischemic Attack: A Pooled Analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trials. Pan Y, Elm JJ, Li H, Easton JD, Wang Y, Farrant M, Meng X, Kim AS, Zhao X, Meurer WJ, Liu L, Dietrich D, Wang Y, Johnston SC. JAMA Neurol; 2019 Dec 01; 76(12):1466-1473. PubMed ID: 31424481 [Abstract] [Full Text] [Related]
27. Ticagrelor-Aspirin Versus Clopidogrel-Aspirin Among CYP2C19 Loss-of-Function Carriers With Minor Stroke or Transient Ischemic Attack in Relation to Renal Function: A Post Hoc Analysis of the CHANCE-2 Trial. Wang A, Xie X, Tian X, Johnston SC, Li H, Bath PM, Zuo Y, Jing J, Lin J, Wang Y, Zhao X, Li Z, Jiang Y, Liu L, Meng X, Wang Y. Ann Intern Med; 2022 Nov 01; 175(11):1534-1542. PubMed ID: 36315949 [Abstract] [Full Text] [Related]
29. Ticagrelor Versus Clopidogrel in Minor Stroke or Transient Ischemic Attack With Intracranial Artery Stenosis: A Post Hoc Analysis of CHANCE-2. Wang C, Jia W, Jing J, Meng X, Wang A, Xu Q, Zhang X, Pan Y, Xie X, Johnston SC, Bath PM, Lin J, Jiang Y, Li H, Wang Y, Zhao X, Liu L, Li Z, Wang Y, CHANCE‐2 Investigators. J Am Heart Assoc; 2023 Nov 07; 12(21):e031611. PubMed ID: 37889172 [Abstract] [Full Text] [Related]
30. Homocysteine Level Predicts Response to Dual Antiplatelet in Women With Minor Stroke or Transient Ischemic Attack: Subanalysis of the CHANCE Trial. Li J, Wang Y, Li H, Zuo Z, Lin J, Wang A, Zhao X, Liu L, Wang Y, CHANCE Investigators. Arterioscler Thromb Vasc Biol; 2020 Mar 07; 40(3):839-846. PubMed ID: 31941381 [Abstract] [Full Text] [Related]
31. Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial. Wang Y, Chen W, Lin Y, Meng X, Chen G, Wang Z, Wu J, Wang D, Li J, Cao Y, Xu Y, Zhang G, Li X, Pan Y, Li H, Zhao X, Liu L, Lin J, Dong K, Jing J, Johnston SC, Wang D, Wang Y, PRINCE Protocol Steering Group. BMJ; 2019 Jun 06; 365():l2211. PubMed ID: 31171523 [Abstract] [Full Text] [Related]
32. F2R Polymorphisms and Clopidogrel Efficacy and Safety in Patients With Minor Stroke or TIA. Pan Y, Wangqin R, Li H, Wang Y, Meng X, Johnston SC, Simon T, Lin J, Zhao X, Liu L, Wang D, Wang Y. Neurology; 2021 Jan 05; 96(1):e1-e9. PubMed ID: 33093222 [Abstract] [Full Text] [Related]
33. Effect of Hypertension on Efficacy and Safety of Ticagrelor-Aspirin Versus Clopidogrel-Aspirin in Minor Stroke or Transient Ischemic Attack. Wang A, Meng X, Tian X, Johnston SC, Li H, Bath PM, Zuo Y, Xie X, Jing J, Lin J, Wang Y, Zhao X, Li Z, Jiang Y, Liu L, Wang F, Wang Y, Huang P, Chen G, Wang Y, CHANCE-2 Investigators. Stroke; 2022 Sep 05; 53(9):2799-2808. PubMed ID: 35656824 [Abstract] [Full Text] [Related]
34. Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial. Tillman H, Johnston SC, Farrant M, Barsan W, Elm JJ, Kim AS, Lindblad AS, Palesch YY, Easton JD. JAMA Neurol; 2019 Jul 01; 76(7):774-782. PubMed ID: 31034032 [Abstract] [Full Text] [Related]
35. Effectiveness and safety of high dose clopidogrel plus aspirin in ischemic stroke patients with the single CYP2C19 loss-of-function allele: a randomized trial. Wu H, Song H, Dou L, Gao B, Pan Y, Dong M, Chen Q, Li J, Song L, Liu C, Li B, Chu W. BMC Neurol; 2020 Oct 29; 20(1):395. PubMed ID: 33121452 [Abstract] [Full Text] [Related]
36. CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study. McDonough CW, McClure LA, Mitchell BD, Gong Y, Horenstein RB, Lewis JP, Field TS, Talbert RL, Benavente OR, Johnson JA, Shuldiner AR. J Am Heart Assoc; 2015 May 27; 4(6):e001652. PubMed ID: 26019129 [Abstract] [Full Text] [Related]
37. Empiric treatment with aspirin and ticagrelor is the most cost-effective strategy in patients with minor stroke or transient ischemic attack. Narasimhalu K, Chan J, Ang YK, De Silva DA, Tan KB. Int J Stroke; 2024 Feb 27; 19(2):209-216. PubMed ID: 37679898 [Abstract] [Full Text] [Related]
38. Assessment of the End Point Adjudication Process on the Results of the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: A Secondary Analysis. Farrant M, Easton JD, Adelman EE, Cucchiara BL, Barsan WG, Tillman HJ, Elm JJ, Kim AS, Lindblad AS, Palesch YY, Zhao W, Pauls K, Walsh KB, Martí-Fàbregas J, Bernstein RA, Johnston SC. JAMA Netw Open; 2019 Sep 04; 2(9):e1910769. PubMed ID: 31490536 [Abstract] [Full Text] [Related]
39. Effect of ticagrelor versus clopidogrel on platelet reactivity measured by thrombelastography in patients with minor stroke or TIA. Yang Y, Chen W, Pan Y, Yan H, Meng X, Liu L, Wang Y, Wang Y. Aging (Albany NY); 2020 Oct 16; 12(20):20085-20094. PubMed ID: 33065552 [Abstract] [Full Text] [Related]
40. Association Between CYP2B6 Polymorphisms and Efficacy of Clopidogrel in Minor Stroke or Transient Ischemic Attack. Qiu X, Zhang Y, Gu H, Jiang Y, Pan Y, Jiang Y, Meng X, Wang Y, Zhao X, Li H, Wang X, Wang Y, Li Z, CHANCE Investigators. Stroke; 2023 Jul 16; 54(7):1770-1776. PubMed ID: 37264909 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]